A Modern Approach to
Cancer Testing

IONIQ Sciences is at the forefront of early cancer detection

Cancer is a scourge on society. One in two Americans will be diagnosed with cancer during their lifetime and one in five will die. The five-year cancer survival rates approach 90% when diagnosed in the earliest stages of the disease versus just 10% in the latest stages. 

We believe it doesn’t have to be this way. 

Expanding from a
Single Cancer
Test to a
Multi-Cancer Screen

Early detection saves lives and money by detecting cancer at its earliest, most-treatable stages. We're well-positioned to develop a Multi-Cancer Screen by leveraging our lung test, breast test, proprietary technology, substantial bioimpedance database, and our deep clinical experience.

IONIQ Development Pipeline

ProLung Test - FDA Breakthrough Device
Breast Cancer Test
Multi-Cancer Screen
LUNA 3 next-gen, portable platform

Clinical Data

Deep clinical evidence library with data collected from more than 1,400 subjects demonstrating dramatic improvement over today's standard of care

Breakthrough Device

IONIQ's ProLung Test designated “Breakthrough Device” by US FDA for its life-enhancing potential

Premier Clinical Sites

More than 25 premier cancer institutions across 3 continents have participated in our clinical trials

World-Class Advisors

Collaborating with medical and scientific experts

Intellectual Property

Robust, growing intellectual portfolio of 22 issued and filed patents plus expert know-how

Years in the Making

IONIQ Recent News

IONIQ to Present at LD Micro Invitational XIII

Salt Lake City, UT, May 30, 2023 – ProLung, Inc. dba IONIQ Sciences, Inc. (“IONIQ” or the “Company”) announced today that Mr. Jared Bauer, CEO, will present in-person at the 13th annual LD Micro Invitational at the Luxe Sunset Boulevard Hotel in Los Angeles, California on June

Empowered Patient Podcast with Jared Bauer, CEO of IONIQ Sciences

Salt Lake City, UT, May 19, 2023 – We’re pleased to announce that Jared Bauer, IONIQ Sciences CEO, was interviewed on the Empowered Patient Podcast in their recent episode, “Using Bioimpedance-Based Technology for Early Detection of Cancer.” Mr. Bauer highlights the core technology of IONIQ’s

Dr. Richard Ferguson is IONIQ’s Clinical Trial Ambassador

Salt Lake City, UT, April 14, 2023 – IONIQ Sciences is pleased to announce that Richard Ferguson, MD is our Clinical Trial Ambassador. Dr. Ferguson is helping ensure that IONIQ’s clinical trial enrollment is appropriately diverse (race, ethnicity, gender and backgrounds). Dr. Ferguson is currently

Standards & Certifications

Meet the Team

Proud to be part of BioHive, the Nations Fastest Growing Life Science Hub.

By embracing diversity and collaboration, BioHive has become the fastest-growing life science community in America. And our innovations are improving the lives of millions of patients.